IMRX...$2.96...Hod...🥳
georgie18
Member Level
Re: georgie18 post# 686256
Wednesday, June 18, 2025 12:18:40 PM
Post#
686320
of 686363
IMRX...$2.52...🥳
georgie18
Member Level
Re: georgie18 post# 394514
Wednesday, June 18, 2025 9:37:41 AM
Post#
394519
of 394537
IMRX...$2.19...🥳...Hod...
IMRX...$1.97...🥳
georgie18
Member Level
Re: georgie18 post# 394472
Tuesday, June 17, 2025 4:04:27 PM
Post#
394503
of 394513
IMRX...$1.83...🥳... https://schrts.co/dSUxnurH ...Oversold 30 minute Chart and a Reversal Hammer off the bottom...Loaded the $1.70 range dip...
georgie18
Member Level
Re: georgie18 post# 686256
Wednesday, June 18, 2025 12:18:40 PM
Post#
686320
of 686363
IMRX...$2.52...🥳
georgie18
Member Level
Re: georgie18 post# 394514
Wednesday, June 18, 2025 9:37:41 AM
Post#
394519
of 394537
IMRX...$2.19...🥳...Hod...
IMRX...$1.97...🥳
georgie18
Member Level
Re: georgie18 post# 394472
Tuesday, June 17, 2025 4:04:27 PM
Post#
394503
of 394513
IMRX...$1.83...🥳... https://schrts.co/dSUxnurH ...Oversold 30 minute Chart and a Reversal Hammer off the bottom...Loaded the $1.70 range dip...
Recent IMRX News
- Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting • GlobeNewswire Inc. • 04/21/2026 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/20/2026 08:16:11 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/20/2026 08:10:12 PM
- Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond • GlobeNewswire Inc. • 04/20/2026 01:00:00 PM
- Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/06/2026 08:05:00 PM
- Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival • GlobeNewswire Inc. • 03/17/2026 08:35:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2026 01:29:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 01:09:20 PM
- Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 03/06/2026 12:45:00 PM
- Immuneering to Present at the Leerink Global Healthcare Conference • GlobeNewswire Inc. • 03/02/2026 09:05:00 PM
- Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/18/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:44:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:37:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:32:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:22:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:14:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:10:18 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 01/22/2026 02:03:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/21/2026 02:09:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 09:07:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/15/2026 01:06:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/14/2026 01:10:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/07/2026 09:10:10 PM
- Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP • GlobeNewswire Inc. • 01/07/2026 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2026 09:50:06 PM
